Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adapted Antibiotherapy vs Tetracycline in Hurley Stage 2 Hidradenitis Suppurativa
NCT05821478Phase 3Recruiting
- Sponsor
- Institut Pasteur
- Start
- May 2025
- Primary completion
- Feb 2027
- Modality
- Reversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ceftriaxone, metronidazole, rifampicin and moxifloxacin in hidradenitis suppurativa (HS) (2 arms), sponsored by Institut Pasteur. Primary endpoint: Percentage of patients reaching clinical remission at 12 weeks. Started May 2025; status: recruiting.
02
Drugs
ceftriaxonemetronidazolerifampicinmoxifloxacin
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT05821478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05821478.